A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—To assess efficacy and tolerability of insulin detemir or NPH insulin added to oral therapy for type 2 diabetes in a treat-to-target titration protocol. RESEARCH DESIGN AND METHODS—Individuals (n = 476) with HbA1c (A1C) 7.5–10.0% were randomized to addition of twice-daily insulin detemir or NPH insulin in a parallel-group, multicenter trial. Over 24 weeks, insulin doses were titrated toward prebreakfast and predinner plasma glucose targets of ≤6.0 mmol/l (≤108 mg/dl). Outcomes assessed included A1C, percentage achieving A1C ≤7.0%, risk of hypoglycemia, and body weight. RESULTS—At 24 weeks, A1C had decreased by 1.8 and 1.9% (from 8.6 to 6.8 and from 8.5 to 6.6%) for detemir and NPH, respectively (NS). In both groups, 70% of participants achieved an A1C ≤7.0%, but the proportion achieving this without hypoglycemia was higher with insulin detemir than with NPH insulin (26 vs. 16%, P = 0.008). Compared with NPH insulin, the risk for all hypoglycemia with insulin detemir was reduced by 47% (P < 0.001) and nocturnal hypoglycemia by 55% (P < 0.001). Mean weight gain was 1.2 kg with insulin detemir and 2.8 kg with NPH insulin (P < 0.001), and the difference in baseline-adjusted final weight was −1.58 (P < 0.001). CONCLUSIONS—Addition of basal insulin to oral drug therapy in people with suboptimal control of type 2 diabetes achieves guideline-recommended A1C values in most people with aggressive titration. Insulin detemir compared with NPH insulin achieves this with reduced hypoglycemia and less weight gain.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The decrease in A1C from triple therapy was greater at 6 months than that of conventional therapy and the superiority was maintained at 3 years.1061”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1061]
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · BMC Medical Research Methodology · doi:10.1186/1471-2288-1-2 · Cited by 2,755
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Glycemic Control From 1988 to 2000 Among U.S. Adults Diagnosed With Type 2 Diabetes
Koro, C. E., Bowlin, S. J., Bourgeois, N., & Fedder, D. O. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.17 · Cited by 648
Research works printed but not linked: 1
- Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N: Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes Diabetes Res Clin Pract 66:193–201, 2004 · DOI · Paper page
Cited by
Items 601–627 of 627
Basalinsulin selbst titrieren lassen oder nicht? Das hängt vom Patienten ab
Stirban, O. A. (2016) · Info Diabetologie · doi:10.1007/s15034-016-0951-8
Beer, K. A. (2016) · Physician Assistant Clinics · doi:10.1016/j.cpha.2016.08.005
Barrieren gegen die Insulintherapie bei Typ-2-Diabetes überwinden
Jäger-Becker, D. (2016) · Info Diabetologie · doi:10.1007/s15034-016-1015-9
Optimising insulin therapy to individual need
Hamson, K. (2018) · Practice Nursing · doi:10.12968/pnur.2018.29.sup3.s9
A practical approach and algorithm for intensifying beyond basal insulin in type 2 diabetes
Goldenberg, R., Assimakopoulos, P., Gilbert, J. D., Gottesman, I. S., & Yale, J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13337
Aggarwal, A., Pande, A. K., & Wadhwa, R. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_41_18
Influencia de la terapia antidiabética en la respuesta al tratamiento de la disfunción eréctil
Gutiérrez, L. S. (2017) · Gredos (University of Salamanca) · doi:10.14201/gredos.137163
Bueno, A. B., Castaño, A. M., & Rodríguez, Á. (2013) · Drug Discovery · doi:10.1002/9781118354483.ch6
What Next After Metformin? Guidelines and Indian Context
Hb, C. (2017) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2017.05.555658
Zhu, D., Li, X., Ji, J., Lu, J., Jia, W., Ji, L., & Zhang, P. (2019) · International Journal of Diabetes and Endocrinology · doi:10.11648/j.ijde.20190403.11
Newer Long-Acting Basal Insulin Preparations
Blonde, L. (2017) · Endocrine Practice · doi:10.1016/s1530-891x(20)43535-9
La terapia insulinica nel diabete mellito tipo 2
Prato, S. D., Sesti, G., Bonadonna, R. C., Consoli, A., Dotta, F., Fanelli, C. G., Mannucci, E., Miccoli, R., Pontiroli, A. E., Pozzilli, P., et al. (2011) · CINECA IRIS Institutial research information system (University of Pisa)
Seminarios de la Fundación Española de Reumatología
Saigí, I., & Pérez, A. (2012)
Mingo, A. G., Criado, J. C. H., Prez, E. P., & Alegra, R. (2008) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(08)73227-2 · Cited by 1
Hypoglycemia in Diabetes Mellitus
Alsahli, M., & Gerich, J. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_19 · Cited by 1
(2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3280d5f7e9
Fanelli, C. G., Lucidi, P., Bolli, G. B., & Porcellati, F. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_22-1 · Cited by 2
Hypoglycemia in Diabetes Mellitus
Alsahli, M., & Gerich, J. E. (2015) · Springer eBooks · doi:10.1007/978-3-319-20797-1_19-1
Insulin Therapy in Type 2 Diabetes
Wyne, K. L., & Mora, P. (2007) · CRC Press eBooks · doi:10.3109/9780849379581-15
Current literature in diabetes
(2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.720
Shaefer, C. F. (2009) · Insulin · doi:10.1016/s1557-0843(09)80016-x
Macías-Batista, A., Martínez, I. P., & de Pablos-Velasco, P. L. (2008) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(08)76264-8
Assessment of basal insulin adherence in people with type 2 diabetes
Nørlev, J. T. D. (2024) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau771502052
Zartab, S., & Abbasian, H. (2025) · PLoS ONE · doi:10.1371/journal.pone.0333186
Kaliuzhnaia, O. S., & Khokhlenkova, N. (2025) · ScienceRise Biological Science · doi:10.15587/2519-8025.2025.349033
Bolli, G. B., Home, P., Lepore, M., Riddle, M. C., Porcellati, F., Fanelli, C. G., Lucidi, P., Yki‐Järvinen, H., Becker, R. H. A., & Owens, D. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70751
Self-citationThe Role of Diabetes Technology in Primary Care
Martens, T. W. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.09.001
Metadata
- Authors
- Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group
- Affiliations
- Aarhus University Hospital (DK)
- Leicester Royal Infirmary (GB)
- Out-Patient Clinic, NZOZ Eskulap, Gniewkowo, Poland
- Out-Patient Clinic, Novo Nordisk, Bagsværd, Denmark
- Novo Nordisk (Denmark) (DK)
- Newcastle University (GB)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-06-01
- Volume
- 29
- Issue
- 6
- Pages
- 1269-1274
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2149194615
- Cited by
- 627
- References
- 36
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 10 · 2021: 11 · 2020: 13 · 2019: 11 · 2018: 16 · 2017: 15 · 2016: 24 · 2015: 31 · 2014: 44 · 2013: 59 · 2012: 55
- FWCI
- 48.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin detemir, NPH insulin, basal insulin, type 2 diabetes, insulin-naive patients, oral glucose-lowering agents, adjunctive therapy, glycemic control, HbA1c, hypoglycemia, nocturnal hypoglycemia, weight gain
- MeSH terms
- Insulin Detemir, Administration, Oral, Adult, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin, Isophane, Weight Gain, Body Mass Index, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.